Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Leukemia, Myeloid, Acute 2Leukemia 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × lestaurtinib × Clear all
NCT00469859 2017-03-15

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Completed
14 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

NCT00079482 2016-07-21

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
224 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡